Group One Trading’s Avidity Biosciences RNAM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-38,400
| Closed | -$2.77M | – | 8568 |
|
|
2025
Q4 | $2.77M | Sell |
38,400
-55,000
| -59% | -$3.55M | ﹤0.01% | 1989 |
|
|
2025
Q3 | $4.07M | Buy |
93,400
+75,400
| +419% | +$3.05M | 0.01% | 1660 |
|
|
2025
Q2 | $511K | Sell |
18,000
-4,600
| -20% | -$137K | ﹤0.01% | 3402 |
|
|
2025
Q1 | $667K | Sell |
22,600
-3,800
| -14% | -$118K | ﹤0.01% | 2813 |
|
|
2024
Q4 | $768K | Buy |
26,400
+18,800
| +247% | +$786K | ﹤0.01% | 2801 |
|
|
2024
Q3 | $349K | Buy |
+7,600
| New | +$330K | ﹤0.01% | 3128 |
|
|
2024
Q2 | – | Sell |
-1,200
| Closed | -$30.6K | – | 7373 |
|
|
2024
Q1 | $30.6K | Sell |
1,200
-3,800
| -76% | -$59.6K | ﹤0.01% | 5106 |
|
|
2023
Q4 | $45.3K | Sell |
5,000
-23,200
| -82% | -$155K | ﹤0.01% | 5143 |
|
|
2023
Q3 | $180K | Buy |
28,200
+27,400
| +3,425% | +$236K | ﹤0.01% | 3894 |
|
|
2023
Q2 | $8.87K | Sell |
800
-600
| -43% | -$7.53K | ﹤0.01% | 6456 |
|
|
2023
Q1 | $21.5K | Sell |
1,400
-3,500
| -71% | -$77K | ﹤0.01% | 5450 |
|
|
2022
Q4 | $109K | Buy |
+4,900
| New | +$73.1K | ﹤0.01% | 4367 |
|
Other funds holding RNAM
Group One Trading's RNAM Position: Q1 2026 in Review
Group One Trading sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 18,571 shares — an estimated $1.34M sold.
Group One Trading first reported a position in RNAM in Q1 2023 and held it in 9 quarters. The position peaked at $1.71M in Q3 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.
- Group One Trading reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
- Group One Trading sold 18,571 Avidity Biosciences shares in Q1 2026, an estimated $1.34M.
- Group One Trading first reported a position in Avidity Biosciences in Q1 2023 and held it in 9 quarters.
- Group One Trading's Avidity Biosciences position peaked at $1.71M in Q3 2025.
- 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.
Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.